Literature DB >> 3872793

Interpretive criteria for temocillin disk diffusion susceptibility testing.

P C Fuchs, A L Barry, C Thornsberry, R N Jones.   

Abstract

The susceptibility of 677 clinical bacterial isolates to temocillin was determined by broth microdilution and disk diffusion methods for the purpose of evaluating disks with three different temocillin concentrations and determining the temocillin disk diffusion interpretive criteria. The 60 microgram temocillin disk provided the highest interpretive accuracy (96.2%), although the 30 microgram disk differed by having only three (1.2%) additional minor interpretive errors. Based on available temocillin pharmacokinetics and recommended dosage schedules, the minimum inhibitory concentration breakpoints chosen were: greater than or equal to 32 micrograms/ml = resistant and less than or equal to 16 micrograms/ml = susceptible. The corresponding disk diffusion zone diameter breakpoints for the 60 microgram disk were less than or equal to 17 mm and greater than or equal to 21 mm; zone diameters of 18-20 mm were considered intermediate. For the 30 microgram disk these were less than or equal to 15 mm, greater than or equal to 19 mm and 16-18 mm respectively.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872793     DOI: 10.1007/bf02148656

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  7 in total

1.  BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Authors:  B Slocombe; M J Basker; P H Bentley; J P Clayton; M Cole; K R Comber; R A Dixon; R A Edmondson; D Jackson; D J Merrikin; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

2.  In vitro activity of temocillin, a new beta-lactamase-stable penicillin active against enterobacteria.

Authors:  D Greenwood; A Cowlishaw; A Eley
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

3.  In vitro activity of temocillin (BRL 17421), a novel beta-lactamase-stable penicillin.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

4.  Antibacterial activity and beta-lactamase stability of temocillin.

Authors:  K Jules; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

5.  Comparative in vitro and in vivo activity of temocillin (BRL 17421) and ampicillin against Haemophilus influenzae type b.

Authors:  R Yogev; W Glogowski; E Connor
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  Temocillin: in vitro activity against 734 selected clinical isolates, including beta-lactamase-producing strains.

Authors:  P C Fuchs; A L Barry; R N Jones; C Thornsberry
Journal:  Diagn Microbiol Infect Dis       Date:  1984-01       Impact factor: 2.803

7.  In vitro activity of BRL 17421 against Haemophilus influenzae, Neisseria gonorrhoeae, and Branhamella catarrhalis.

Authors:  P Piot; E Van Dyck
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

  7 in total
  10 in total

1.  Increasing incidence of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in Belgian hospitals.

Authors:  M De Laveleye; T D Huang; P Bogaerts; C Berhin; C Bauraing; P Sacré; A Noel; Y Glupczynski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-17       Impact factor: 3.267

2.  Resurrecting Old β-Lactams: Potent Inhibitory Activity of Temocillin against Multidrug-Resistant Burkholderia Species Isolates from the United States.

Authors:  Elise T Zeiser; Scott A Becka; Melissa D Barnes; Magdalena A Taracila; John J LiPuma; Krisztina M Papp-Wallace
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

3.  In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.

Authors:  A Van Dalem; M Herpol; F Echahidi; C Peeters; I Wybo; E De Wachter; P Vandamme; D Piérard
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Septicemia with Ewingella americana.

Authors:  K Devreese; G Claeys; G Verschraegen
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

5.  In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units.

Authors:  Y Glupczynski; T-D Huang; C Berhin; G Claeys; M Delmée; L Ide; G Ieven; D Pierard; H Rodriguez-Villalobos; M Struelens; J Vaneldere
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

6.  Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.

Authors:  S Bonacorsi; F Fitoussi; S Lhopital; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

7.  Direct susceptibility testing by disk diffusion on clinical samples: a rapid and accurate tool for antibiotic stewardship.

Authors:  L Coorevits; J Boelens; G Claeys
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-20       Impact factor: 3.267

8.  Increasing proportion of carbapenemase-producing Enterobacteriaceae and emergence of a MCR-1 producer through a multicentric study among hospital-based and private laboratories in Belgium from September to November 2015.

Authors:  Te Din Huang; Pierre Bogaerts; Catherine Berhin; Martin Hoebeke; Caroline Bauraing; Youri Glupczynski
Journal:  Euro Surveill       Date:  2017-05-11

9.  In vitro activity of 20 antibiotics against Cupriavidus clinical strains.

Authors:  Clémence Massip; Mathieu Coullaud-Gamel; Cécile Gaudru; Lucie Amoureux; Anne Doleans-Jordheim; Geneviève Hery-Arnaud; Hélène Marchandin; Eric Oswald; Christine Segonds; Hélène Guet-Revillet
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

10.  Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study.

Authors:  Julie Oosterbos; Maaike Schalkwijk; Steven Thiessen; Els Oris; Guy Coppens; Katrien Lagrou; Deborah Steensels
Journal:  JAC Antimicrob Resist       Date:  2022-08-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.